Imagion Biosystems has released Change of Director’s Interest Notices for David Ludvigson, Mark Van Asten, and Robert Proulx.
Read the Change in Director’s Interest Notices:
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)